<SEC-DOCUMENT>0001179110-14-008686.txt : 20140516
<SEC-HEADER>0001179110-14-008686.hdr.sgml : 20140516
<ACCEPTANCE-DATETIME>20140516180907
ACCESSION NUMBER:		0001179110-14-008686
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20140509
FILED AS OF DATE:		20140516
DATE AS OF CHANGE:		20140516

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Onconova Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001130598
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		375 PHEASANT RUN
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940
		BUSINESS PHONE:		267-759-3681

	MAIL ADDRESS:	
		STREET 1:		375 PHEASANT RUN
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ONCONOVA THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20090526

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ONCONOVA THERAPEUTICS INC
		DATE OF NAME CHANGE:	20001226

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Guerin Mark Patrick
		CENTRAL INDEX KEY:			0001607714

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36020
		FILM NUMBER:		14852778

	MAIL ADDRESS:	
		STREET 1:		375 PHEASANT RUN
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>edgar.xml
<DESCRIPTION>FORM 3 -
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2014-05-09</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001130598</issuerCik>
        <issuerName>Onconova Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>ONTX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001607714</rptOwnerCik>
            <rptOwnerName>Guerin Mark Patrick</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ONCONOVA THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>375 PHEASANT RUN</rptOwnerStreet2>
            <rptOwnerCity>NEWTOWN</rptOwnerCity>
            <rptOwnerState>PA</rptOwnerState>
            <rptOwnerZipCode>18940</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Accounting Officer</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>600</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>28.81</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2023-10-04</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>30000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>13.48</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2023-12-20</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>6000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>6.30</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2024-03-31</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>24500</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">This option, representing a right to purchase, vests over 4 years, with 25% vesting on October 4, 2014 and 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the issuer.</footnote>
        <footnote id="F2">This option, representing a right to purchase, vests over 4 years in 48 equal monthly installments, subject to continued service to the issuer.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>Mark Guerin</signatureName>
        <signatureDate>2014-05-16</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.POA
<SEQUENCE>2
<FILENAME>ex24guerin.txt
<DESCRIPTION>POWER OF ATTORNEY
<TEXT>
LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes,
constitutes and appoints Ramesh Kumar, Ph.D. and Ajay Bansal as
the undersigned's true and lawful attorney-in-fact, with full
power
and authority as hereinafter described on behalf of and in the
name,
place and stead of the undersigned to:

  (1)  prepare, execute, acknowledge, deliver and file Forms 3,
4,
and 5 (as applicable, including any amendments thereto) with
respect
to the securities of Onconova Therapeutics, Inc., a Delaware
corporation (the "Company"), with the United States Securities
and Exchange Commission, any national securities exchanges and
the Company, as considered necessary or advisable under Section
16(a) of the Securities Exchange Act of 1934 and the rules and
regulations promulgated thereunder, as amended from time to
time (the "Exchange Act");

  (2)  seek or obtain, as the undersigned's representative and
on the undersigned's behalf, information on transactions in the
Company's securities from any third party, including but not
limited to brokers, employee benefit plan administrators and
trustees, and the undersigned hereby authorizes any such third
party to release any such information to the undersigned and
approves
and ratifies any such release of information to the undersigned;
and

  (3)  perform any and all other acts which in the discretion
of such attorney-in-fact are necessary or desirable for and on
behalf
of the undersigned in connection with the foregoing.

The undersigned acknowledges that:

  (1)  this Limited Power of Attorney authorizes, but does not
require, such attorney-in-fact to act in his discretion on
information provided to such attorney-in-fact without independent
verification of such information;

  (2)  any documents prepared and/or executed by such
attorney-in-fact on behalf of the undersigned pursuant to this
Limited Power of Attorney will be in such form and will contain
such information and disclosure as such attorney-in-fact,
in his discretion, deems necessary or desirable;

  (3)  neither the Company nor such attorney-in-fact assumes (i)
any
 liability for the undersigned's responsibility to comply with
the
requirements of the Exchange Act, (ii) any liability of the
undersigned for any failure to comply with such requirements, or
(iii) any obligation or liability of the undersigned for profit
disgorgement under Section 16(b) of the Exchange Act; and

  (4)  this Limited Power of Attorney does not relieve the
undersigned
from responsibility for compliance with the undersigned's
obligations
under the Exchange Act, including without limitation the
reporting
requirements under Section 16 of the Exchange Act.

  The undersigned hereby gives and grants the foregoing attorney-
in-fact
full power and authority to do and perform all and every act and
thing
whatsoever requisite, necessary or appropriate to be done in and
about
the foregoing matters as fully to all intents and purposes as the
undersigned might or could do if present, hereby ratifying all
that
such attorney-in-fact of, for and on behalf of the undersigned,
shall
lawfully do or cause to be done by virtue of this Limited Power
of
Attorney.

  This Limited Power of Attorney shall remain in full force and
effect
until revoked by the undersigned in a signed writing delivered to
such
 attorney-in-fact.

  IN WITNESS WHEREOF, the undersigned has caused this Limited
Power
of Attorney to be executed as of this 8th day of May, 2013.

/s/ Mark Guerin
______________________________
Name: Mark Guerin

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
